Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jun;210(2):109-19.
doi: 10.1007/s00213-010-1819-6. Epub 2010 Apr 7.

Kappa opioids and the modulation of pain

Affiliations
Review

Kappa opioids and the modulation of pain

Bronwyn Kivell et al. Psychopharmacology (Berl). 2010 Jun.

Abstract

Background and rationale: Pain is a complex sensory experience, involving cognitive factors, environment (setting, society, and culture), experience, and gender and is modulated significantly by the central nervous system (CNS). The mechanisms by which opioid analgesics work are understood, but this class of drugs is not ideal as either an analgesic or anti-hyperalgesic. Accordingly, considerable effort continues to be directed at improved understanding of nociceptor function and development of selective analgesics that do not have the unwanted effects associated with opioid analgesics.

Objective: The purpose of this paper is to provide a review of the role of KOP receptors in the modulation of pain and highlight several chemotypes currently being explored as peripherally restricted KOP ligands.

Results: A growing body of literature has shown that KOP receptors are implicated in a variety of behavioral pain models. Several different classes of peripherally restricted peptidic and nonpeptidic KOP agonists have been identified and show utility in treating painful conditions.

Conclusion: The pharmacological profile of KOP agonists in visceral pain models suggest that peripherally restricted KOP agonists are potentially useful for a variety of peripheral pain states. Further, clinical investigation of peripherally restricted KOP agonists will help to clarify the painful conditions where KOP agonists will be most effective.

PubMed Disclaimer

References

    1. Clin J Pain. 2010 Jan;26 Suppl 10:S10-5 - PubMed
    1. J Pharmacol Exp Ther. 1989 Mar;248(3):1269-75 - PubMed
    1. Anesth Analg. 1993 Jan;76(1):182-91 - PubMed
    1. Neuropharmacology. 2007 Dec;53(8):930-41 - PubMed
    1. Adv Exp Med Biol. 2003;521:148-60 - PubMed

MeSH terms

LinkOut - more resources